期刊
HUMAN MUTATION
卷 37, 期 2, 页码 209-215出版社
WILEY
DOI: 10.1002/humu.22931
关键词
cystic fibrosis; CFTR; splicing mutation; exon skipping; antisense oligonucleotide
资金
- Foundation of Science and Technology, Portugal (FCT/MCTES/PIDDAC)
- FCT/MCTES/PIDDAC, Portugal [PTDC/SAU-GMG/122299/2010, UID/MULTI/04046/2013]
- Fundação para a Ciência e a Tecnologia [PTDC/SAU-GMG/122299/2010] Funding Source: FCT
Cystic fibrosis (CF), the most common lifethreatening genetic disease in Caucasians, is caused by similar to 2,000 different mutations in the CF transmembrane conductance regulator (CFTR) gene. A significant fraction of these (similar to 13%) affect pre-mRNA splicing for which novel therapies have been somewhat neglected. We have previously described the effect of the CFTR splicing mutation c.2657+5G>A in IVS16, showing that it originates transcripts lacking exon 16 as well as wild-type transcripts. Here, we tested an RNA-based antisense oligonucleotide (AON) strategy to correct the aberrant splicing caused by this mutation. Two AONs (AON1/2) complementary to the pre-mRNA IVS16 mutant region were designed and their effect on splicing was assessed at the RNA and protein levels, on intracellular protein localization and function. To this end, we used the 2657+5G>A mutant CFTR minigene stably expressed in HEK293 Flp-In cells that express a single copy of the transgene. RNA data from AON1-treated mutant cells show that exon 16 inclusion was almost completely restored (to 95%), also resulting in increased levels of correctly localized CFTR protein at the plasma membrane (PM) and with increased function. A novel two-color CFTR splicing reporter minigene developed here allowed the quantitative monitoring of splicing by automated microscopy localization of CFTR at the PM. The AON strategy is thus a promising therapeutic approach for the specific correction of alternative splicing. (C) 2015 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据